share_log

Immuneering Says FDA Clears Investigational New Drug Application for RAS Mutant Solid Tumors Therapy

Immuneering Says FDA Clears Investigational New Drug Application for RAS Mutant Solid Tumors Therapy

免疫接種公司稱FDA批准了RAS突變實體瘤治療的研究新藥申請
MT Newswires ·  2022/09/30 07:11

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論